Cohen Romain, Colle Raphaël, Pudlarz Thomas, Heran Maximilien, Duval Alex, Svrcek Magali, André Thierry
Department of Medical Oncology, Assistance Publique des Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Sorbonne Université, F-75012 Paris, France.
Centre de Recherche Saint Antoine, Équipe Instabilité des Microsatellites et Cancer, Équipe Labellisée par la Ligue Nationale Contre le Cancer et SIRIC CURAMUS, INSERM UMRS 938, Sorbonne Université, F-75012 Paris, France.
Cancers (Basel). 2021 Mar 8;13(5):1149. doi: 10.3390/cancers13051149.
Microsatellite instability (MSI) is a tumor phenotype related to a deficient DNA mismatch repair system (dMMR). This phenotype, observed in 5% of metastatic mCRC but 10-18% of localized CRC, is associated with high tumor mutational burden with highly immunogenic neoantigens. It has emerged as a major predictive biomarker for the efficacy of ICIs. In this review, we will present a comprehensive overview of the literature concerning the efficacy of ICIs in MSI/dMMR mCRC, with a focus on new developments in first-line metastatic setting. Then, we will present current and future challenges of immuno-oncology for patients with MSI/dMMR metastatic CRC.
微卫星不稳定性(MSI)是一种与DNA错配修复系统缺陷(dMMR)相关的肿瘤表型。这种表型在5%的转移性结直肠癌(mCRC)中可见,但在10-18%的局限性结直肠癌中可见,与具有高度免疫原性新抗原的高肿瘤突变负担相关。它已成为免疫检查点抑制剂(ICI)疗效的主要预测生物标志物。在本综述中,我们将全面概述有关ICI在MSI/dMMR mCRC中疗效的文献,重点关注一线转移性环境中的新进展。然后,我们将介绍MSI/dMMR转移性结直肠癌患者免疫肿瘤学的当前和未来挑战。